Logo image of QGEN

QIAGEN N.V. (QGEN) Stock Fundamental Analysis

USA - NYSE:QGEN - NL0015002CX3 - Common Stock

45.94 USD
+0.2 (+0.44%)
Last: 9/19/2025, 8:04:00 PM
45.94 USD
0 (0%)
After Hours: 9/19/2025, 8:04:00 PM
Fundamental Rating

6

QGEN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. QGEN has an excellent profitability rating, but there are some minor concerns on its financial health. QGEN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

QGEN had positive earnings in the past year.
In the past year QGEN had a positive cash flow from operations.
In the past 5 years QGEN has always been profitable.
In the past 5 years QGEN always reported a positive cash flow from operatings.
QGEN Yearly Net Income VS EBIT VS OCF VS FCFQGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of QGEN (6.41%) is better than 81.82% of its industry peers.
Looking at the Return On Equity, with a value of 10.65%, QGEN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
QGEN has a Return On Invested Capital of 8.66%. This is amongst the best in the industry. QGEN outperforms 83.64% of its industry peers.
QGEN had an Average Return On Invested Capital over the past 3 years of 7.25%. This is significantly below the industry average of 15.41%.
The 3 year average ROIC (7.25%) for QGEN is below the current ROIC(8.66%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.41%
ROE 10.65%
ROIC 8.66%
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
QGEN Yearly ROA, ROE, ROICQGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15

1.3 Margins

With an excellent Profit Margin value of 18.30%, QGEN belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
In the last couple of years the Profit Margin of QGEN has declined.
QGEN has a Operating Margin of 26.86%. This is amongst the best in the industry. QGEN outperforms 94.55% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN has a better Gross Margin (64.18%) than 85.45% of its industry peers.
In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
Industry RankSector Rank
OM 26.86%
PM (TTM) 18.3%
GM 64.18%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
QGEN Yearly Profit, Operating, Gross MarginsQGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
QGEN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.
QGEN Yearly Shares OutstandingQGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
QGEN Yearly Total Debt VS Total AssetsQGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

QGEN has an Altman-Z score of 3.99. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
QGEN has a better Altman-Z score (3.99) than 78.18% of its industry peers.
The Debt to FCF ratio of QGEN is 2.91, which is a good value as it means it would take QGEN, 2.91 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of QGEN (2.91) is better than 80.00% of its industry peers.
QGEN has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of QGEN (0.25) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 2.91
Altman-Z 3.99
ROIC/WACC1.13
WACC7.65%
QGEN Yearly LT Debt VS Equity VS FCFQGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

QGEN has a Current Ratio of 1.61. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.61, QGEN is not doing good in the industry: 69.09% of the companies in the same industry are doing better.
A Quick Ratio of 1.35 indicates that QGEN should not have too much problems paying its short term obligations.
QGEN has a Quick ratio of 1.35. This is in the lower half of the industry: QGEN underperforms 69.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.35
QGEN Yearly Current Assets VS Current LiabilitesQGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.20% over the past year.
The Earnings Per Share has been growing by 8.40% on average over the past years. This is quite good.
QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.15%.
The Revenue has been growing slightly by 5.32% on average over the past years.
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%

3.2 Future

QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.02% yearly.
QGEN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.38% yearly.
EPS Next Y7.88%
EPS Next 2Y8.09%
EPS Next 3Y8.68%
EPS Next 5Y8.02%
Revenue Next Year5.25%
Revenue Next 2Y5.47%
Revenue Next 3Y5.89%
Revenue Next 5Y7.38%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
QGEN Yearly Revenue VS EstimatesQGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
QGEN Yearly EPS VS EstimatesQGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

6

4. Valuation

4.1 Price/Earnings Ratio

QGEN is valuated rather expensively with a Price/Earnings ratio of 19.55.
QGEN's Price/Earnings ratio is rather cheap when compared to the industry. QGEN is cheaper than 85.45% of the companies in the same industry.
QGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.38.
With a Price/Forward Earnings ratio of 17.69, QGEN is valued on the expensive side.
83.64% of the companies in the same industry are more expensive than QGEN, based on the Price/Forward Earnings ratio.
QGEN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.86.
Industry RankSector Rank
PE 19.55
Fwd PE 17.69
QGEN Price Earnings VS Forward Price EarningsQGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaply inside the industry as 87.27% of the companies are valued more expensively.
83.64% of the companies in the same industry are more expensive than QGEN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.08
EV/EBITDA 13.89
QGEN Per share dataQGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.48
PEG (5Y)2.33
EPS Next 2Y8.09%
EPS Next 3Y8.68%

2

5. Dividend

5.1 Amount

QGEN has a yearly dividend return of 0.55%, which is pretty low.
Compared to an average industry Dividend Yield of 0.54, QGEN pays a better dividend. On top of this QGEN pays more dividend than 90.91% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, QGEN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.55%

5.2 History

QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
QGEN Yearly Dividends per shareQGEN Yearly Dividends per shareYearly Dividends per share 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2Y8.09%
EPS Next 3Y8.68%
QGEN Yearly Income VS Free CF VS DividendQGEN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

QIAGEN N.V.

NYSE:QGEN (9/19/2025, 8:04:00 PM)

After market: 45.94 0 (0%)

45.94

+0.2 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-07 2025-11-07/amc
Inst Owners87.24%
Inst Owner Change-22.15%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap9.96B
Analysts75
Price Target52.82 (14.98%)
Short Float %3.15%
Short Ratio4.57
Dividend
Industry RankSector Rank
Dividend Yield 0.55%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date07-02 2025-07-02 (0.25)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.7%
Min EPS beat(2)-2.4%
Max EPS beat(2)7.8%
EPS beat(4)2
Avg EPS beat(4)1.23%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.51%
EPS beat(12)8
Avg EPS beat(12)3.69%
EPS beat(16)12
Avg EPS beat(16)5.44%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.16%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.61%
Revenue beat(12)3
Avg Revenue beat(12)-0.41%
Revenue beat(16)7
Avg Revenue beat(16)0.85%
PT rev (1m)2.48%
PT rev (3m)4.48%
EPS NQ rev (1m)0.43%
EPS NQ rev (3m)0.96%
EPS NY rev (1m)0%
EPS NY rev (3m)0.53%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)1.09%
Valuation
Industry RankSector Rank
PE 19.55
Fwd PE 17.69
P/S 4.88
P/FCF 20.08
P/OCF 14.76
P/B 2.84
P/tB 15.58
EV/EBITDA 13.89
EPS(TTM)2.35
EY5.12%
EPS(NY)2.6
Fwd EY5.65%
FCF(TTM)2.29
FCFY4.98%
OCF(TTM)3.11
OCFY6.78%
SpS9.41
BVpS16.17
TBVpS2.95
PEG (NY)2.48
PEG (5Y)2.33
Profitability
Industry RankSector Rank
ROA 6.41%
ROE 10.65%
ROCE 11.67%
ROIC 8.66%
ROICexc 10.87%
ROICexgc 46.44%
OM 26.86%
PM (TTM) 18.3%
GM 64.18%
FCFM 24.31%
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexcg growth 3Y-31.24%
ROICexcg growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 2.91
Debt/EBITDA 1.2
Cap/Depr 94.78%
Cap/Sales 8.78%
Interest Coverage 250
Cash Conversion 91.61%
Profit Quality 132.83%
Current Ratio 1.61
Quick Ratio 1.35
Altman-Z 3.99
F-Score8
WACC7.65%
ROIC/WACC1.13
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)12.2%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%6.06%
EPS Next Y7.88%
EPS Next 2Y8.09%
EPS Next 3Y8.68%
EPS Next 5Y8.02%
Revenue 1Y (TTM)5.15%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%7.49%
Revenue Next Year5.25%
Revenue Next 2Y5.47%
Revenue Next 3Y5.89%
Revenue Next 5Y7.38%
EBIT growth 1Y21.82%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.62%
EBIT Next 5Y14.77%
FCF growth 1Y31.74%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y29.99%
OCF growth 3Y1.77%
OCF growth 5Y15.28%